Imbruvica and Esbriet drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Imbruvica and Esbriet. Common interactions include death among males.

The phase IV clinical study analyzes what interactions people who take Imbruvica and Esbriet have. It is created by eHealthMe based on reports of 7 people who take Imbruvica and Esbriet from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Mar, 28, 2023

7 people who take Imbruvica and Esbriet together, and have interactions are studied.


What is Imbruvica?

Imbruvica has active ingredients of ibrutinib. It is often used in chronic lymphocytic leukemia (cll). eHealthMe is studying from 50,141 Imbruvica users for its effectiveness, alternative drugs and more.

What is Esbriet?

Esbriet has active ingredients of pirfenidone. eHealthMe is studying from 35,507 Esbriet users for its effectiveness, alternative drugs and more.

Number of Imbruvica and Esbriet reports submitted per year:

Imbruvica and Esbriet drug interactions.

Common Imbruvica and Esbriet drug interactions by gender *:

female:

n/a

male:

  1. Death
  2. Dizziness
  3. Dyspnoea
  4. Fall
  5. Cardiac disorder
  6. Constipation
  7. Pericardial effusion

Common Imbruvica and Esbriet drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

  1. Death
  2. Dizziness
  3. Dyspnoea
  4. Fall
  5. Cardiac disorder
  6. Pericardial effusion

* Approximation only. Some reports may have incomplete information.

Do you take Imbruvica and Esbriet?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Imbruvica and Esbriet:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Imbruvica side effects:

Browse all side effects of Imbruvica:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Esbriet side effects:

Browse all side effects of Esbriet:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Imbruvica interactions:

Browse all interactions between Imbruvica and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Esbriet interactions:

Browse all interactions between Esbriet and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on ibrutinib and pirfenidone (the active ingredients of Imbruvica and Esbriet, respectively), and Imbruvica and Esbriet (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Imbruvica and Esbriet.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: